Breast Cancer | Specialty

Breast Cancer Survivor Noreen Fraser Turns Anger into Action

March 10th 2011

Noreen Fraser clearly recalls the day in 2003 when her doctor informed her that the breast cancer she had been diagnosed with 2 years earlier had metastasized to her bones

NCCN Launches Consumer-Friendly Versions

March 9th 2011

NCCN Launches Consumer-Friendly Versions of Guideline Publications Breast cancer and non-small cell lung cancer are the inaugural entries in a new series of publications the National Comprehensive Cancer Network (NCCN) is rolling out in the coming months.

FDA Requests Label Change for Generic Docetaxel

March 9th 2011

The FDA has requested that the generic drug manufacturer Hospira change the planned label for its generic formulation of docetaxel.

Dr. Pearlstone on Practice Changing Studies

March 8th 2011

Oncology Community Must Guide Public on Gene Testing Nuances

March 8th 2011

The genuine revolution in our understanding of the genetic basis of malignant disease has led to a corresponding interest in defining the risk of developing a particular disease for both individuals and specific populations.

Dr. Pearlstone on Technological Challenges

March 8th 2011

Dr. Pearlstone Describes the Young Cancer Coalition

March 8th 2011

Dr. David Pearlstone, from John Theurer Cancer Center, Describes the Young Cancer Coalition

Dr. Perez on her Anticipated Results for ASCO and SABCS

March 8th 2011

From the Editor: Electronic Alerts Would Help Oncologists Manage Therapy

March 7th 2011

It was not so long ago that designing an optimal treatment plan for an individual cancer patient required only a confirmed histologic/morphologic diagnosis of a particular tumor type and appropriate staging, which was surgically based in most solid tumors.

Tools to Help Patients Navigate Their Treatment Path

March 7th 2011

Monica Knoll is no stranger to cancer. Her sister is a breast cancer survivor and her father died from esophageal cancer. Still, she was not prepared for a breast cancer diagnosis in 2000

SABCS 2010: Obesity Ups Risk of Recurrence for Some Women With HER2-Negative Breast Cancer

March 4th 2011

Being obese at the time operable breast cancer is diagnosed is associated with inferior outcomes in women with estrogen receptor (ER) or progesterone receptor (PR)positive, HER2-negative breast cancer.

Triple Receptor-Negative Breast Cancer: Current and Future Treatments

March 4th 2011

Breast cancer is the number one malignancy diagnosed in women in the United States. In 2009, it was estimated that more than 190,000 individuals would be diagnosed with breast cancer and approximately 40,000 would die from the disease.

Resection and Reconstruction of a Solitary Sternal Metastasis After Mastectomy for Breast Cancer: A Case Report and Review of the Literature

March 3rd 2011

In May 2005, a 25-year-old female presented to her primary care physician complaining of a newly palpable breast mass that had grown to several centimeters over the course of a few months.

10 Tips for Breast Cancer Patients During Treatment

March 3rd 2011

10 helpful tips to remember during treatment for patients struggling with breast cancer

False-Positive Mammograms Lead to Anxiety and Quality-of-Life Issues

March 2nd 2011

A false-positive result on a mammogram may trigger anxiety and decrease quality of life, and the effects may remain apparent a year later, new data suggest.

Breastfeeding May Benefit Childhood Cancer Survivors

March 2nd 2011

For women who have survived childhood cancer, breastfeeding may help counter some of the long-term complications that occur as a result of their prior cancer treatments, researchers say.

SABCS Coverage: Adding Everolimus to Tamoxifen Improves Outcomes in Metastatic Breast Cancer

March 2nd 2011

Everolimus (Afinitor) added to tamoxifen delayed tumor progression in patients with hormone receptor (HR)-positive, HER2-negative, advanced metastatic breast cancer

SABCS Coverage: Denosumab Bests Zoledronic Acid at Preventing Bone Complications in Patients With Breast Cancer

March 2nd 2011

Investigators for Study 136 say that an additional 4 months of follow-up data have confirmed earlier findings that denosumab (Xgeva) is superior to zoledronic acid (Zometa) at preventing skeletal-related events

SABCS Coverage: Fulvestrant Prolongs Time to Progression in Breast Cancer

March 2nd 2011

Women with untreated advanced breast cancer had a trend toward greater clinical benefit with fulvestrant (Faslodex) versus anastrozole (Arimidex) as first-line hormonal therapy

SABCS Coverage: MA.27 Study Finds Exemestane and Anastrozole Comparable

March 2nd 2011

Exemestane (Aromasin) was no better than anastrozole (Arimidex) at reducing cancer recurrence in postmenopausal women with hormone receptor-positive primary breast cancer